What the Evidence Says About Psychedelic-Assisted Therapy for Addiction in 2026
Ibogaine, psilocybin, MDMA, ketamine — the clinical trial landscape is broader than the headlines suggest, but so are the caveats.
Body: [Balanced evidence review: psilocybin for AUD (Johns Hopkins, NYU), ibogaine for OUD (Stanford, Kentucky’s state-funded research), MDMA (field setback after 2024 FDA rejection, what changed), ketamine (already approved for depression, off-label for AUD), what the meta-analyses actually show, safety concerns, regulatory pathway. Concludes with: “promising but not yet ready for routine care.” 900 words.]
Sources Cited
- 01.Ahttps://heal.nih.govNIH HEAL
- 02.Ahttps://clinicaltrials.govClinicalTrials.gov
Filed Under
Peer-Reviewed ResearchMAT — BuprenorphineFederal
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Psilocybin Lowered Inflammation Markers in Parkinson's Patients. Don't Let Anyone Tell You What That Proves.
A JAMA Psychiatry study reports lower inflammation markers in people with Parkinson's disease after psilocybin. It was small and had no control group. What it can and cannot tell clinicians.
Science & MedicineDoubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?
A meta-analysis of 41 THC experiments finds that doubling the dose from 5 to 10 mg raised the self-reported high by about 15 percent and left anxiety unchanged. What it means for people who use, and for providers.
Science & MedicineTwo Postdocs Are Telling the DEA That Schedule I Is Not a Place to Park Uncertainty
Students for Sensible Drug Policy, two early-career scientists and MindState Design Labs asked the DEA for a hearing on placing five tryptamines in Schedule I. What the proposal covers, what it doesn't, and who it could hit first.